The planned interim analysis confirms the accuracy of the sample size calculations and statistical power for EMACC, the primary endpoint.…
Boston (June 27, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company…
Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using…
Planegg/Martinsried, June 27, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on…
GEN2’s dose-escalation trial, GVO-1102, will establish the Recommended Phase 2 Dose (RP2D), followed immediately by an expansion phase into 3…
GRAND RAPIDS, Mich., June 26, 2024 /PRNewswire/ -- On June 24, 2024, Rep. Hillary Scholten (MI-03) joined members of the National Blood…
Results of an international multi-center study to evaluate the accuracy of the ClarityDX Prostate screening test are now available to…
Halifax, Nova Scotia--(Newsfile Corp. - June 26, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona")…
Ongoing Study is Investigating RenovoGem™ to treat Locally Advanced Pancreatic CancerLOS ALTOS, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc.…
PALO ALTO, CA / ACCESSWIRE / June 26, 2024 / Bioz, Inc., a pioneer in AI-driven research solutions, is delighted…